Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)

NCTID	NCT06461702 (View at clinicaltrials.gov)
Description	This study is a single arm, open, single dose escalation trial aimed at evaluating the safety and tolerability of YOLT-101 administration in patients with familial hypercholesterolemia; Determination of YOLT-101 OBD; Preliminary evaluation of the effects of single administration of YOLT-101 on plasma lipid and lipoprotein levels. Note: OBD is defined as the dosage at which plasma PCSK9 protein levels decrease between 60% and 95% from baseline on the 28th day after YOLT-101 administration. OBD ≤ Maximum Tolerable Dose (MTD). (Show More)
Development Status	Active
Indication	Familial Hypercholesterolemia
Disease Ontology Term	DOID:13810
Compound Name	YOLT-101
Sponsor	The First Affiliated Hospital of Bengbu Medical University
Funder Type	Other
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	13 (ESTIMATED)
Results Posted	Not Available

No.of Trial Sites	1
Locations	China

Has US IND	False
FDA Designations
Recent Updates	FDA cleared IND application in June 2025